|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 11/00 | (2006.01) |
| C07D 239/69 | (2006.01) | ||
| C07D 515/08 | (2006.01) |
| (11) | Number of the document | 3946595 |
| (13) | Kind of document | T |
| (96) | European patent application number | 20722087.2 |
| Date of filing the European patent application | 2020-04-02 | |
| (97) | Date of publication of the European application | 2022-02-09 |
| (45) | Date of publication and mention of the grant of the patent | 2023-11-15 |
| (46) | Date of publication of the claims translation | 2023-12-27 |
| (86) | Number | PCT/US2020/026331 |
| Date | 2020-04-02 |
| (87) | Number | WO 2020/206080 |
| Date | 2020-10-08 |
| (30) | Number | Date | Country code |
| 201962828699 P | 2019-04-03 | US |
| (72) |
HADIDA RUAH, Sara Sabina , US
ISHIHARA, Yoshihiro , US
KRENITSKY, Paul , US
MCCARTNEY, Jason , US
MELILLO, Vito , US
MILLER, Mark Thomas , US
SILINA, Alina , US
UY, Johnny , US
ZHOU, Jinglan , US
|
| (73) |
Vertex Pharmaceuticals Incorporated ,
50 Northern Avenue, Boston, MA 02210,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Cistinės fibrozės transmembraninio laidumo reguliatorių moduliuojantys agentai |
| CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS |
| Payment date | Validity (years) | Amount | |
| 2026-03-18 | 7 | 162.00 EUR |
| 2027-04-02 |